Obagi Medical Devices: Short Term Huge Gainer On Buyout, Long Term Investment Without One

By Scott Matusow:Lately there has been a lot of buzz on a company I have been writing about called Obagi Medical Products (OMPI). I was first alerted some months ago to this company as a potential buyout candidate and informed by anonymous sources that larger pharmas were interested in buying the company out. Lately, speculation of a buyout has become stronger based on the poison pill being voted down by shareholders by over a 2 to 1 margin at the recent annual shareholders meeting.As well, Voce Capital Management, a major shareholder of Obagi publicly revealed its opposition to the poison pill implemented by the Board of Directors of Obagi. Sources continue to say that an $18-$20 "all cash" buyout of the firm may finally be close to being announced.But what if a buyout does not occur soon? Examining this company, I have really liked what I have found. For starters,Complete Story »

By Scott Matusow:I chose the title to this article based on the old adage of "sh**t or get off the pot" -- my sentiments regarding the ongoing Obagi Medical Products (OMPI) saga that has escalated to its current point after VOCE Capital Management wrote an updated note to Obagi shareholders

By Medhanie:There has been a great deal of hope and speculation that Obagi Medical Products (OMPI) is an imminent target for a buyout. This hope was given a big boost when shareholders voted down a poison pill introduced by the company board and executives. It was a resounding statement that shareholders made, telling the board and CEO we want to sell. On the face of it, this makes perfect sense.

By Scott Matusow:Another chapter has been written on the nearly year-long effort by Voce Capital management to get Obagi Medical Products (OMPI) sold. On Monday, 12/3/12, Voce made public another letter sent to the Obagi Board of Directors (BOD).

By Scott Matusow:The buyout talk is heating up concerning Obagi Medical Devices (OMPI) as Cantor Fitzgerald's Irina Rivkind said the company could be attractive to "multiple suitors." The analyst named Valeant (

By Scott Matusow:Yesterday, Voce Capital released a letter sent to the Solta Medical (SLTM) Board of Directors (BOD) expressing its displeasure in the company's appointment of Mark M. Sieczkarek as interim CEO of the company.

By Scott Matusow:As many who follow me know, I wrote several articles covering Obagi Medical Products (OMPI) as a key acquisition target for several larger players in its field. Obagi engages in marketing and selling skin care products which include: Obagi Nu-Derm Systems, Obagi Condition & Enhance Systems, and Obagi-C Rx Systems, just to name a few.

In an exclusive interview with ET Now, Harish Bhat, Chairman, Tata Global, says having a chairman of the board who is in a position of hostility to the major promoter company which is Tata Sons is really detrimental to the interest of all stakeholders including the minority shareholders of the company. Edited excerpts Take us through the events, the flow of events at the board meeting yesterday. What is it that prompted you to propose Santhanakrishnan’s name as the chairman of the company.